Following the FDAs ruling in September 2023, injectable BPC 157 is no longer available from compounding pharmacies due to concerns regarding its adverse risk profile
Check your marketing for compliance
Less common reports include fatigue 1224 hours after dosing, injection-site redness, and brief flushing
The published human data supporting BPC-157 may not be strong, but, he argued, forbidding American companies from providing it would move it deeper into a market with no production or sourcing standards, no physician, no monitoring, and no record. That view was echoed by Jeffrey Egler, the chief medical officer at the telehealth company Noom
BPC-157 is not a licensed medicine in the UK
The right next step depends on the reader's evidence, safety, cost, access, and provider-review needs